In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Qatar between 2014 – 2015

BMC Microbiology

Jacques F Meis¹  Muna Al Maslamani⁵  Sanjay Doiphode²  Godwin Wilson⁴  Mariamma Abraham²  Ola Al Sharabasi²  Ferry Hagen³  Anand Deshmukh² 

[1]Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands

[2]Microbiology Division, Hamad General Hospital, Doha, Qatar

[3]Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands

[4]Microbiology Division, Al Khor Hospital, Doha, Qatar

[5]Department of Infectious Diseases, Hamad General Hospital, Doha, Qatar

关键词: Qatar;    Antimicrobial susceptibility testing;    Brucellosis;    Brucella melitensis;   

Others  :  1221665
DOI  :  10.1186/s12866-015-0458-9

 received in 2014-12-03, accepted in 2015-06-01,  发布年份 2015

【 摘 要 】

Background

Brucellosis is one of the most common zoonotic disease affecting humans and animals and is endemic in many parts of the world including the Gulf Cooperation Council region (GCC). The aim of this study was to identify the species and determine the antimicrobial susceptibility pattern of Brucella strains isolated from clinical specimens, from Qatar.

Results

We evaluated 231 Brucella isolates. All isolates were identified as B. melitensis. All the isolates were susceptible to doxycycline, tetracycline, streptomycin, gentamicin, trimethoprim / sulfamethoxazole and ciprofloxacin except rifampicin, where 48 % of the strains showed elevated MICs (>1 mg/L). The rifampicin-resistance related hotspots within the rpoB gene were amplified and sequenced using PCR and no rpoB mutations were found in strains with rifampicin MICs of >2 mg/L.

Conclusion

This study identified B. melitensis as the etiological agent of brucellosis in Qatar. No resistant isolates were detected among conventionally used antimicrobial agents.

【 授权许可】

   
2015 Deshmukh et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Fact sheet N173. WHO, Geneva, Switzerland; 1997.
• [2]Seleem MN, Boyle SM, Sriranganathan N. Brucellosis: a re-emerging zoonosis. Vet Microbiol. 2010; 140:392-398.
• [3]Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis. 2006; 6:91-99.
• [4]Corbel MJ. Brucellosis in humans and animals. Geneva (Switzerland): World Health Organization; 2006.
• [5]Robichaud S, Libman M, Behr M, Rubin E. Prevention of laboratory-acquired brucellosis. Clin Infect Dis. 2004; 38:e119-e122.
• [6]Lista F, Reubsaet FA, De Santis R, Parchen RR, de Jong AL, Kieboom J et al.. Reliable identification at the species level of Brucella isolates with MALDI-TOF-MS. BMC Microbiol. 2011; 11:267. BioMed Central Full Text
• [7]Methods of antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Approved guidelines- second edition. CLSI document M45-A2. Clinical and Laboratory Standard Institute, Wayne, PA; 2010.
• [8]Performance standard for antimicrobial susceptibility testing: twenty-fourth informational supplement. CLSI document M100-S24. Clinical and Laboratory Standard Institute, Wayne, PA; 2014.
• [9]Abdel-Maksoud M, House B, Wasfy M, Abdel-Rahman B, Pimentel G, Roushdy G et al.. In vitro antibiotic susceptibility testing of Brucella isolates from Egypt between 1999 and 2007 and evidence of probable rifampin resistance. Ann Clin Microbiol Antimicrob. 2012; 11:24. BioMed Central Full Text
• [10]Marianelli C, Ciuchini F, Tarantino M, Pasquali P, Adone R. Genetic bases of the rifampicin resistance phenotype in Brucella spp. J Clin Microbiol. 2004; 42:5439-5443.
• [11]Valdezate S, Navarro A, Medina-Pascual MJ, Carrasco G, Saéz-Nieto JA. Molecular screening for rifampicin and fluoroquinolone resistance in a clinical population of Brucella melitensis. J Antimicrob Chemother. 2010; 65:51-53.
• [12]Gür D, Kocagöz S, Akova M, Unal S. Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob Agents Chemother. 1999; 43:2337.
• [13]Bayram Y, Korkoca H, Aypak C, Parlak M, Cikman A, Kilic S et al.. Antimicrobial susceptibilities of Brucella isolates from various clinical specimens. Int J Med Sci. 2011; 8:198-202.
• [14]Marianelli C, Graziani C, Santangelo C, Xibilia MT, Imbriani A, Amato R et al.. Molecular epidemiological and antibiotic susceptibility characterization of Brucella isolates from humans in Sicily, Italy. J Clin Microbiol. 2007; 45:2923-2928.
• [15]Hashim R, Ahmad N, Mohamed Zahidi J, Tay BY, Mohd Noor A, Zainal S et al.. Identification and in vitro antimicrobial susceptibility of Brucella species isolated from human brucellosis. Int J Microbiol. 2014; 2014:596245.
• [16]Kaya O, Akçam FZ, Yaylı G. Investigation of the in vitro activities of various antibiotics against Brucella melitensis strains. Turk J Med Sci. 2012; 42:145-148.
• [17]López-merino A, Contreras-rodríguez A, Migranas-ortiz R, Orrantia-gradín R, Hernández-oliva GM, Torres Y et al.. Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis. 2004; 36:636-638.
• [18]Solís García del Pozo J, Solera J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. PLoS One. 2012; 7:e32090.
• [19]Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME et al.. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med. 2007; 4:e317.
• [20]Pappas G, Siozopoulou V, Akritidis N, Falagas ME. Doxycycline-rifampicin: physicians’ inferior choice in brucellosis or how convenience reigns over science. J Infect. 2007; 54:459-462.
• [21]Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008; 336:701-704.
• [22]Colmenero JD, Fernandez-Gallardo LC, Agundez JA, Sedeno J, Benitez J, Valverde E. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother. 1994; 38:2798-2802.
• [23]Grayson ML, Kucers A. Kucers’ the use of antibiotics a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. 6th ed. Hodder Arnold, London; 2010.
• [24]Rahil AI, Othman M, Ibrahim W, Mohamed MY. Brucellosis in Qatar: a retrospective cohort study. Qatar Med J. 2014; 1:25.
• [25]Goldstein BP. Resistance to rifampicin: a review. J Antibiot (Tokyo). 2014; 67:625-630.
• [26]Sandalakis V, Psaroulaki A, De Bock PJ, Christidou A, Gevaert K, Tsiotis G et al.. Investigation of rifampicin resistance mechanisms in Brucella abortus using MS-driven comparative proteomics. J Proteome Res. 2012; 11:2374-2385.
• [27]Sayan M, Kilic S, Uyanik MH. Epidemiological survey of rifampicin resistance in clinic isolates of Brucella melitensis obtained from all regions of Turkey. J Infect Chemother. 2012; 18:41-46.
• [28]Lubani MM, Dudin KI, Sharda DC, Ndhar DS, Araj GF, Hafez HA et al.. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J. 1989; 8:75-78.
• [29]Kinsara A, Al-Mowallad A, Osoba AO. Increasing resistance of Brucellae to co-trimoxazole. Antimicrob Agents Chemother. 1999; 43:1531.
• [30]Easmon CS, Crane JP, Blowers A. Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies. J Antimicrob Chemother. 1986; 18 Suppl D:43-48.
• [31]Akova M, Gur D, Livermore DM, Kocagoz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother. 1999; 43:1298-1300.
• [32]Pappas G, Christou L, Akritidis N, Tsianos EV. Quinolones for brucellosis: treating old diseases with new drugs. Clin Microbiol Infect. 2006; 12:823-825.
• [33]Falagas ME, Bliziotis IA. Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob Agents Chemother. 2006; 50:22-33.